Compare ICHR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICHR | HRMY |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2016 | 2020 |
| Metric | ICHR | HRMY |
|---|---|---|
| Price | $76.46 | $30.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $49.50 | $44.11 |
| AVG Volume (30 Days) | ★ 919.2K | 884.3K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $947,652,000.00 | $868,453,000.00 |
| Revenue This Year | $20.51 | $19.75 |
| Revenue Next Year | $17.08 | $12.88 |
| P/E Ratio | ★ N/A | $56.89 |
| Revenue Growth | 11.61 | ★ 21.51 |
| 52 Week Low | $13.15 | $25.52 |
| 52 Week High | $75.35 | $40.87 |
| Indicator | ICHR | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 70.34 | 48.58 |
| Support Level | $16.14 | $25.92 |
| Resistance Level | N/A | $30.96 |
| Average True Range (ATR) | 5.30 | 1.13 |
| MACD | 0.25 | -0.09 |
| Stochastic Oscillator | 92.94 | 40.34 |
Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.